Prophase Labs, Inc. declined 10.58% in intraday trading. The company released an investor presentation on July 16, 2025, which included forward-looking statements regarding its strategy, plans, objectives, and initiatives. The presentation also mentioned the company's expectations for future revenue growth, the timeline for commercializing its BE-Smart Esophageal Cancer Test, and its efforts to collect accounts receivables.
Comments
No comments yet